Premium
This is an archive article published on June 16, 2021

AstraZeneca vaccine vs Delta variant of Covid-19: Two doses found crucial

A new scientific analysis has found that two doses of Covid-19 vaccines are highly effective in preventing hospitalisation due to the Delta variant. How was the analysis conducted, and what does this mean?

Covid vaccine doses, AstraZeneca vs Delta, Covid-19 vaccine doses, Delta variant vaccine, Coronavirus cases, express explained, explained health, indian express newsThe analysis gives effectiveness data of two vaccines.

New findings from the UK show that vaccines are effective against Delta variant, a major contributor to the second wave of Covid-19 in India, and which has replaced the Alpha variant as the dominant strain in the UK.

What are the new findings?

A new scientific analysis, published by Public Health England, has found that two doses of Covid-19 vaccines are highly effective in preventing hospitalisation due to B.1.617.2, now known as the Delta variant. Importantly, it showed no deaths among those vaccinated.

The analysis gives effectiveness data of two vaccines. Pfizer-BioNTech’s mRNA vaccine was found 96% effective in preventing hospitalisation after two doses. The Oxford-AstraZeneca vaccine was found 92% effective after two doses. The Indian version of this vaccine, Covishield from Serum Institute, is among the vaccines being administered in the country.

Story continues below this ad

How was the analysis conducted?

Researchers from the London School of Hygiene and Tropical Medicine, London and Guys, and St Thomas’s Hospital NHS Trust, London, linked all symptomatic Covid-19 cases between April 12 and June 4 to the Emergency Care Dataset (ECDS) which records all admission via emergency departments in England. The analysis included 14,019 cases of the Delta variant – 166 of whom were hospitalised.

The analysis showed that the vaccines’ effectiveness in preventing hospitalisation with Delta was similar to that seen with Alpha — (94%) after the first dose and 96% after the second dose of the Pfizer vaccine; and 71% after the first dose and 92% after the second dose of the Oxford-AstraZeneca vaccine.

“These findings indicate very high levels of protection against hospitalisation with the Delta variant with 1 or 2 doses of either vaccine,” the researchers concluded in the paper, which is yet to be peer-reviewed.

Story continues below this ad

Newsletter | Click to get the day’s best explainers in your inbox

What are the takeaways?

Matt Hancock, Health and Social Care Secretary, said it is vital to get both doses as soon as they are offered to you, to gain maximum protection against all existing and emerging variants.

On Tuesday, AstraZeneca said that real-world data from PHE suggest that vaccine effectiveness against milder symptomatic disease, although significant, was lower — 74% against the Alpha variant and 64% against the Delta variant. “The higher efficacy against severe disease and hospitalisation is supported by recent data showing strong T-cell response to Covid-19 Vaccine AstraZeneca, which should correlate with high and durable protection,” AstraZeneca said.

The data also suggests that Covishield, which accounts for 88% of doses being given in India, will have a significant impact in reducing hospitalisation in the country.

Story continues below this ad

“This real-world evidence shows that COVID-19 Vaccine AstraZeneca provides a high level of protection against the Delta variant, which is currently a critical area of concern given its rapid transmission,” said Mene Pangalos, Executive Vice President, BioPharmaceuticals R&D at AstraZaneca said.

Are there other new findings on Delta?

On June 11, PHE said in a technical briefing that 28-day case fatality rate for Delta remains low (0.1%) “… though mortality is a lagged indicator and the vast majority of cases are still within the 28 days of follow-up required”.

On Tuesday, The Lancet published an analysis of the Delta variant in Scotland, covering the period between April and June 6. The researchers analysed 19,543 confirmed SARS-CoV-2 infections, of whom 377 were admitted to hospital.

Story continues below this ad

The researchers said that the Delta variant in Scotland was found mainly in younger, more affluent groups. The risk of hospital admission was approximately doubled in those with the Delta variant when compared to the Alpha variant.

Kaunain Sheriff M is an award-winning investigative journalist and the National Health Editor at The Indian Express. He is the author of Johnson & Johnson Files: The Indian Secrets of a Global Giant, an investigation into one of the world’s most powerful pharmaceutical companies. With over a decade of experience, Kaunain brings deep expertise in three areas of investigative journalism: law, health, and data. He currently leads The Indian Express newsroom’s in-depth coverage of health. His work has earned some of the most prestigious honours in journalism, including the Ramnath Goenka Award for Excellence in Journalism, the Society of Publishers in Asia (SOPA) Award, and the Mumbai Press Club’s Red Ink Award. Kaunain has also collaborated on major global investigations. He was part of the Implant Files project with the International Consortium of Investigative Journalists (ICIJ), which exposed malpractices in the medical device industry across the world. He also contributed to an international investigation that uncovered how a Chinese big-data firm was monitoring thousands of prominent Indian individuals and institutions in real time. Over the years, he has reported on several high-profile criminal trials, including the Hashimpura massacre, the 2G spectrum scam, and the coal block allocation case. Within The Indian Express, he has been honoured three times with the Indian Express Excellence Award for his investigations—on the anti-Sikh riots, the Vyapam exam scam, and the abuse of the National Security Act in Uttar Pradesh. ... Read More

Latest Comment
Post Comment
Read Comments
Advertisement
Advertisement
Advertisement
Advertisement